Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance

PharmacoEconomics

Volumn 20, Issue 8, 2002, Pages 513-528

  Kuti, Joseph L ^a   Capitano, Blair ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; CHLAMYDOPHILA PNEUMONIAE; COST EFFECTIVENESS ANALYSIS; HAEMOPHILUS INFLUENZAE TYPE A; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LEGIONELLA PNEUMOPHILA; MONOTHERAPY; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIA; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIA;

EID: 0036330531     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220080-00002     Document Type: Review

References (71)

1. Community-acquired pneumonia
2. Prognosis and outcomes of patients with community-acquired pneumonia
3. Trends in infectious diseases mortality in the United States
4. The cost of treating community-acquired pneumonia
5. Decreased susceptibility of streptococcus pneumoniae to fluoroquinolones in Canada
6. Antimicrobial resistance in streptococcus pneumoniae: An overview
7. The role of atypical pathogens: Mycoplasma pneumoniae, chlamydia pneumoniae, and legionella pneumophila in respiratory infection
8. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
9. Increasing prevalence of multidrug-resistant streptococcus pneumoniae in the United States
10. Antimicrobial resistance among clinical isolates of streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rate since 1994-1995
11. Macrolide-resistant streptococcus pneumoniae in Canada during the 1998-1999: Prevalence of mef(A) and erm(B) and susceptibilities to ketolides
12. Pharmacodynamic factors of antibiotic efficacy
13. Antibiotic pharmacodynamics: Its role in patient care
14. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis
15. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
16. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
17. Antibiotic pharmacokinetic and pharmacodynamic attributes for community-acquired respiratory tract infection
18. Pharmacodynamics and pharmacokinetics of levofloxacin
19. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
20. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
21. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
22. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
23. Pharmacodynamics of levofloxacin and ciprofloxacin against S. pneumoniae
24. Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: Optimizing antimicrobial therapy in respiratory tract infections
25. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae
26. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
27. Continuous infusion beta-lactams: A pharmacodynamic approach
28. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
29. The pharmacokinetic and pharmacodynamic attributes of oral cephalosporins for use in switch therapy
30. Are there differences in the treatment of community-acquired pneumonia between a community and university hospital
31. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
32. Economic impact of streamlining antibiotic administration
33. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach
34. Pharmacoeconomic analysis of piperacillin/tazobactam vs ticarcillin/clavulanate for the treatment of intra-abdominal infections
35. Pharmacoeconomics of antimicrobial therapy
36. Economic considerations in perforated and gangrenous appendicitis: Imipenem-cilastatin versus clindamycin and gentamicin
37. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia
38. Workplace costs associated with acute exacerbations of chronic bronchitis: A comparison of moxifloxacin and levofloxacin
39. Clinical rote of fluoroquinolones in patients with respiratory tract infections
40. The methoxyfluoroquinolones: Gatifloxacin and moxifloxacin
41. The Infectious Disease Society of America. Practice guidelines for the management of community-acquired pneumonia in adults
42. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
43. Respiratory tract pathogens isolated form patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
44. Cost-effectiveness of once-daily oral antimicrobial therapy
45. Cost of oral antibiotic therapy
46. Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia
47. Serum bactericidal activity of ceftazidime: Continuous infusion vs intermittent injections
48. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia
49. Identification of low-risk hospitalized patients with pneumonia: Implications for early conversion to oral antimicrobial therapy
50. Early switch from intravenous to oral cephalosporins I the treatment of hospitalized patients with community-acquired pneumonia
51. Early switch from intravenous to oral antibiotics and early hospital discharge
52. Time to clinical stability in patients hospitalized with community-acquired pneumonia
53. Consequences of intravascular catheter sepsis
54. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia: The optimal duration of therapy
55. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
56. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy
57. Is one day of in-hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of community acquired pneumonia necessary?
58. Is an observation period necessary after intravenous antibiotics are changed to oral administration?
59. A pharmacist-initiated program of intravenous to oral antibiotic conversion
60. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: A 6-month prospective study
61. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team
62. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital
63. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality
64. A prediction rule to identify low-risk patients with community-acquired pneumonia
65. Management of community-acquired pneumonia in the era of pneumococcal resistance
66. Canadian guidelines for the intial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
67. Guidelines for the management of adults with community-acquired pneumonia